1. Home
  2. SUPN vs SPRY Comparison

SUPN vs SPRY Comparison

Compare SUPN & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SUPN
  • SPRY
  • Stock Information
  • Founded
  • SUPN 2005
  • SPRY 2015
  • Country
  • SUPN United States
  • SPRY United States
  • Employees
  • SUPN N/A
  • SPRY N/A
  • Industry
  • SUPN Biotechnology: Pharmaceutical Preparations
  • SPRY Biotechnology: Pharmaceutical Preparations
  • Sector
  • SUPN Health Care
  • SPRY Health Care
  • Exchange
  • SUPN Nasdaq
  • SPRY Nasdaq
  • Market Cap
  • SUPN 1.9B
  • SPRY 1.8B
  • IPO Year
  • SUPN 2012
  • SPRY N/A
  • Fundamental
  • Price
  • SUPN $33.56
  • SPRY $17.88
  • Analyst Decision
  • SUPN Hold
  • SPRY Strong Buy
  • Analyst Count
  • SUPN 2
  • SPRY 4
  • Target Price
  • SUPN $36.00
  • SPRY $28.75
  • AVG Volume (30 Days)
  • SUPN 681.6K
  • SPRY 1.3M
  • Earning Date
  • SUPN 08-05-2025
  • SPRY 08-05-2025
  • Dividend Yield
  • SUPN N/A
  • SPRY N/A
  • EPS Growth
  • SUPN N/A
  • SPRY N/A
  • EPS
  • SUPN 1.11
  • SPRY N/A
  • Revenue
  • SUPN $667,997,000.00
  • SPRY $97,122,000.00
  • Revenue This Year
  • SUPN N/A
  • SPRY N/A
  • Revenue Next Year
  • SUPN $15.74
  • SPRY $170.64
  • P/E Ratio
  • SUPN $30.78
  • SPRY N/A
  • Revenue Growth
  • SUPN 11.82
  • SPRY 971120.00
  • 52 Week Low
  • SUPN $27.05
  • SPRY $8.91
  • 52 Week High
  • SUPN $40.28
  • SPRY $18.90
  • Technical
  • Relative Strength Index (RSI)
  • SUPN 57.11
  • SPRY 56.00
  • Support Level
  • SUPN $32.94
  • SPRY $17.70
  • Resistance Level
  • SUPN $34.21
  • SPRY $18.63
  • Average True Range (ATR)
  • SUPN 1.06
  • SPRY 0.65
  • MACD
  • SUPN 0.04
  • SPRY -0.10
  • Stochastic Oscillator
  • SUPN 56.90
  • SPRY 47.92

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Share on Social Networks: